Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals’ FDA approval of BYSANTI (milsaperidone) for bipolar I and schizophrenia marks a strategic breakthrough, promising a strong exclusivity window, premium pricing, and significant investor upside.

Vanda Pharmaceuticals’ Q4 2025 earnings plunge to –$2.39 EPS, modest 7.6% revenue rise, and FY26 outlook below expectations—investors weigh pipeline promise against widening losses and cash‑burn risks.

Vanda Pharmaceuticals faces legal scrutiny and a negative P/E ratio amid volatile stock; investors weigh risks and future prospects in biotech.

Vanda Pharmaceuticals faces hedge‑fund divestment, fraud claims, and a legal probe while still pitching at JPMorgan Healthcare, testing investor confidence and stock stability.

FDA rejects Vanda’s HETLIOZ® jet‑lag application, citing insufficient real‑world evidence, but the company remains poised to address concerns and seek approval.

Vanda Pharmaceuticals Inc. continues to navigate market fluctuations and invest in its pipeline of innovative treatments for central nervous system disorders.

Vanda Pharmaceuticals Inc. has reported its recent financial performance, with a market capitalization of $286.42 million and a price-to-earnings ratio of -6.42, as the company continues to focus on developing treatments for central nervous system d…

Vanda Pharmaceuticals Inc. has reported a strong first quarter in 2025, driven by commercial success with Fanapt and promising pipeline developments, positioning the company for continued growth and future success.